2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1920

Is There Objective Evidence of Neuropathy in Knee Osteoarthritis Based on Clinical Evaluation?
Abstract Number: 1921

Relation of Sensitization and Conditioned Pain Modulation to Post-Knee Replacement Pain
Abstract Number: 1922

Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
Abstract Number: 1923

Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
Abstract Number: 1924

Mitigating Medication Risk Aversion in the Confident Treatment Decisions for Living with Rheumatoid Arthritis Trial
Abstract Number: 1925

Goal Concordance in Rheumatoid Arthritis: Beyond Pain Reduction, Is There Agreement?
Abstract Number: 1926

Effects of Social Networking on Chronic Disease Management in Rheumatoid Arthritis
Abstract Number: 1927

Do Remission and Low Disease Activity State Go Hand in Hand with Patient’s Perception of Disease Burden and Quality of Life in Systemic Lupus Erythematosus?
Abstract Number: 1928

Patient-Physician Communication about Medication Costs in Rheumatoid Arthritis
Abstract Number: 1929

The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure
Abstract Number: 1930

Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Rheumatoid Arthritis Patients in Clinical Remission
Abstract Number: 1931

Abundance of Plasma Microbial Small RNAs Are Predictive of Improvement in Disease Activity after DMARD Initiation for Rheumatoid Arthritis
Abstract Number: 1932

Complications Following Total Knee Arthroplasty in Inflammatory Versus Osteoarthritis
Abstract Number: 1933

Histological Features and Tissue-Macrophage Phenotype of Synovial Biopsies Identify RA Patients in Sustained Remission at Risk of Disease Flare after Treatment Tapering or Discontinuation
Abstract Number: 1934

microRNA Targeting IL-33 Gene As Biomarker to Predict Subclinical Atherosclerosis in Patients with Early Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].